Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 7/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3635578 | 1.00 | TLR4 (0.50) | TLR4EPHX1ACHEPRKACAAKT1 | |
| SCHEMBL15870614 | 1.00 | TLR4 (0.50) | TLR4EPHX1ACHEPRKACAAKT1 | |
| SCHEMBL18976840 | 1.00 | TLR4 (0.50) | TLR4EPHX1ACHEPRKACAAKT1 | |
| SCHEMBL60344 | 1.00 | TLR4 (0.50) | TLR4EPHX1ACHEPRKACAAKT1 | |
| Urethane SCHEMBL3737671 | 0.92 | TLR4 (0.44) | TLR4EPHX1ACHEPRKACA | |
| SCHEMBL2279209 | 0.88 | TLR4 (0.48) | TLR4EPHX1AKT1 | |
| SCHEMBL1857528 | 0.86 | EPHX1 (0.47) | TLR4EPHX1ACHE | |
| SCHEMBL3635575 | 0.84 | EPHX1 (0.47) | TLR4EPHX1ACHE | |
| SCHEMBL60343 | 0.84 | EPHX1 (0.47) | TLR4EPHX1ACHE | |
| SCHEMBL236414 | 0.84 | EPHX1 (0.47) | TLR4EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 629 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403108-B2 | Non-enzymatic debriding agent and method of use thereof | ALIRA HEALTH BOSTON LLC (US) | 2025-09-02 | — | — | US | claimed |
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| CN-111182880-B | WNT compositions and process from serum-free culture conditions | 安卡萨再生疗法公司 | 2024-01-09 | — | — | CN | claimed |
| US-20230345944-A1 | Purified and Enhanced Hydrogen Peroxide Disinfecting Solution for the Rapid Inactivation of COVID-19 and Other Pathogens | SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT | 2023-11-02 | — | — | US | claimed |
| WO-2023200764-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-10-19 | — | — | WO | claimed |
| CN-108124451-B | Compositions and methods for extracting DNA and RNA from tissue samples | 塞弗德公司 | 2022-09-09 | — | — | CN | claimed |
| US-20210393554-A1 | NANOEMULSION COMPOSITIONS HAVING ENHANCED PERMEABILITY | BLUEWILLOW BIOLOGICS, INC. (US) | 2021-12-23 | — | — | US | claimed |
| US-20200405846-A1 | EMULSION ADJUVANT FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION | BLUEWILLOW BIOLOGICS, INC. | 2020-12-31 | — | — | US | claimed |
| US-20200246449-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2020-08-06 | — | — | US | claimed |
| US-20200237689-A1 | PREVENTION AND TREATMENT OF CORONAVIRUS AND OTHER RESPIRATORY INFECTIONS USING NANOEMULSION COMPOSITIONS | BLUEWILLOW BIOLOGICS, INC. (US) | 2020-07-30 | — | — | US | claimed |
| EP-1814559-A1 | METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-08-08 | — | — | EP | claimed |
| US-7186522-B2 | Using detergents to reduce artifacts during staining of biological samples; medical diagnostics and cervical cancer | CYTYC CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| JP-2007502618-A | — | — | 2007-02-15 | — | — | JP | claimed |
| US-20070003998-A1 | Papanicolau staining process | THIRD WAVE TECHNOLOGIES, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1654387-A2 | MATERIALS AND METHODS FOR CAPTURE OF PATHOGENS AND REMOVAL OF AURINTRICARBOXYLIC ACID FROM A SAMPLE | UNIVERSITY OF SOUTH FLORIDA (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2006045050-A1 | METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-04-27 | — | — | WO | claimed |
| US-20050277130-A1 | Removing aurintricarboxylic acid (ATA), a reverse transcriptase inhibitor, from a blood sample containing ATA and a chaotropic salt for nucleic acid extraction by using urea at a pH of about 8.0; high speed analysis by creating a fibrin aggregate to confine pathogens to facilitate pathogen DNA extraction | UNIVERSITY OF SOUTH FLORIDA | 2005-12-15 | — | — | US | claimed |
| WO-2005021799-A2 | MATERIALS AND METHODS FOR CAPTURE OF PATHOGENS AND REMOVAL OF AURINTRICARBOXYLIC ACID FROM A SAMPLE | UNIVERSITY OF SOUTH FLORIDA (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050014128-A1 | Early Detection of Pathogens in Blood | UNIVERSITY OF SOUTH FLORIDA (US) | 2005-01-20 | — | — | US | claimed |
| US-20040191854-A1 | Papanicolau staining process | CYTYC CORPORATION | 2004-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230345944-A1 | Purified and Enhanced Hydrogen Peroxide Disinfecting Solution for the Rapid Inactivation of COVID-19 and Other Pathogens | CAT, PRDX1, HAO2 | TLR4 4581/4885EPHX1 2463/4885ACHE 1068/4885 |
| US-20200405846-A1 | EMULSION ADJUVANT FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION | DBI, DLAT, ABHD5 | TLR4 173/4885EPHX1 2261/4885ACHE 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.